-
2008
12 February 2008: Press release no. 1, 2008: Phase III program for AVE0010/ZP10 licensed ...
-
Product Pipeline
Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and ...
-
Available Positions
We have one vacant position: Scientist-Department of Molecular Pharmacology ...
ZP1848
Glucagon-like Peptide-2 (GLP-2) is a peptide growth factor that specifically targets and stimulates growth of the intestinal epithelium. In experimental models of small intestinal injury and disease, administration of GLP-2 remarkably enhanced the repair, regeneration and absorptive capacity of the small intestinal mucosa. These findings aroused significant interest for the potential therapeutic use of GLP-2 in the treatment of intestinal disease and injury although the known relative instability of the peptide in the body represented a significant challenge.
At Zealand, we have applied our SIP®-technology and knowledge of peptide stabilization and produced a series of novel GLP-2 peptide analogues with enhanced stability and efficacy. One of these, ZP1848 has been selected and in pre-clinical pharmacological studies has been shown to attenuate small intestinal inflammation and enhance recovery from inflammation in an experimental model of Inflammatory Bowel Diseases (IBD).
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.